CPRX NASDAQ
Catalyst Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.3%
3M: +20.8%
YTD: +36.0%
1Y: +49.7%
3Y: +144.9%
5Y: +472.6%
$31.49
Last traded 2026-07-21 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships11
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-06-30
Earliest Filing
2023-07-21
Latest Filing
partner: 8
supplier: 2
acquirer: 1
Counterparties (Filed by CPRX)
11 relationshipsCompanies named in CPRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Santhera Pharmaceuticals Holdings AG | — | partner | Licensor of vamorolone North American rights and recipient of strategic equity investment | 2023-07-21 | View |
| Santhera Pharmaceuticals (Schweiz) AG | — | partner | Wholly owned subsidiary of Santhera Pharmaceuticals Holdings AG and signatory to the License Agreement | 2023-07-21 | View |
| Santhera Pharmaceuticals Holding AG | — | partner | License and collaboration partner for vamorolone in North America and investor receiving $15 million | 2023-06-23 | View |
| Santhera Pharmaceuticals (Schweiz) AG | — | partner | Wholly-owned subsidiary of Santhera Pharmaceuticals Holding AG executing the License Agreement | 2023-06-23 | View |
| Eisai Co., Ltd. | — | supplier | Sold U.S. rights for FYCOMPA (perampanel) and will provide manufacturing services | 2023-01-30 | View |
| Eisai, Inc. | — | supplier | U.S. subsidiary of Eisai providing transition services | 2023-01-30 | View |
| Eisai | — | acquirer | Catalyst Pharmaceuticals acquired U.S. rights for FYCOMPA and an option for a rare epilepsy asset from Eisai. | 2022-12-22 | View |
| Jacobus Pharmaceutical Company, Inc. | — | partner | Settled patent litigation and sold intellectual property rights to Catalyst Pharmaceuticals, Inc. | 2022-07-12 | View |
| PantherRx Rare LLC | — | partner | Co-defendant in patent litigation settled with Catalyst Pharmaceuticals, Inc. | 2022-07-12 | View |
| SERB SA | — | partner | Patent owner that entered a settlement agreement with Catalyst Pharmaceuticals, Inc. | 2022-07-12 | View |
| DyDo Pharma, Inc. | — | partner | Entered into a License & Supply Agreement for Japanese rights to Firdapse® | 2021-06-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-16 | Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Director Change; Bylaws Amendm | Acquisition | View |
| 2026-07-08 | Officer/Director Change; Shareholder Vote | View | |
| 2026-06-30 | Other Events; Exhibits | View | |
| 2026-06-23 | Other Events | View | |
| 2026-05-07 | Material Agreement; Bylaws Amendment; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-02-25 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-05 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-01 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-28 | Financial Statements and Exhibits | View | |
| 2025-08-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-04 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-23 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-04-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-26 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-24 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR